



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-CD5 [H65] Standard Size Ab04159-10.0

Isotype and Format: Human IgG1, Kappa

Clone Number: H65

Alternative Name(s) of Target: LEU1; T-cell surface glycoprotein CD5; Lymphocyte antigen T1/Leu-1; Tp67 antigen

UniProt Accession Number of Target Protein: P06127

Published Application(s): therapeutic, FC

Published Species Reactivity: Human

Immunogen: The original antibody was generated by immunizing a BALB/c mice with human T cell line HSB-2, which was isolated from a patient with T cell acute lymphocytic leukemia.

Specificity: This antibody binds human CD5, which is a surface glycoprotein that act as a receptor in regulating T-cell proliferation. CD5 is a good immunohistochemical marker for T-cells.

Application Notes: This antibody was used for the generation of a ricin A chain anti-T lymphocyte immunotoxin (H65-RTA) and was examined for its ability to bind to lymphocytes, to inhibit protein synthesis in a cell free system, and to inhibit lymphocyte transformation without affecting hematopoietic progenitor cells as measured by the in vitro colony assays. It was reported that the immunotoxin was an effective agent against immunocompetent T lymphocytes in vitro and may be an effective agent for use in clinical bone marrow transplantation (PMID: 6609971). A safety and efficacy study of this lymphocyte-targeted immunotoxin was conducted in patients with severe acute steroid-resistant graft-versus-host disease (AGVHD) in a phase I-II dose escalation study with group expansion at the two middle doses. It was seen that under appropriate conditions, H65-RTA can produce up to a 98% depletion of T lymphocytes from human bone marrow without decreasing the number of committed hematopoietic progenitor cells. The results indicated that H65-RTA is an immunosuppressive agent useful in treatment of T-cell mediated diseases (PMID: 2180494). This antibody can be used for the detection of CD5 expressed on the surface of T cells using flow cytometry. In a phase I trial in patients with cutaneous T-cell lymphoma, it was reported that H65-RTA can be safely administered in patients and the immunoconjugate can serve as an active drug in the treatment of cutaneous T-cell lymphoma (PMID: 1878584).

Antibody First Published in: Kernan et al. Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin. J Immunol. 1984 Jul;133(1):137-46. [PMID:6609971](#)

Note on publication: Describes the generation of a ricin A toxin conjugated antibody immunotoxin and evaluates its ability to inhibit in vitro T lymphocyte transformation.

Product Form

Size: 100 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.